Finally, our data suggest that IKKβ kinase inhibition therapy may clinically benefit KRAS-driven lung cancer patients by depleting the pool of stem-like TICs, thereby decreasing the risk of tumour recurrence and metastasis. Here, KRAS is linked to neoplasm.